Guggenheim Upgrades Neumora Therapeutics on Breakthrough Obesity Drug Results
Guggenheim upgrades Neumora to Buy with $14 target after impressive preclinical obesity data shows up to 26% weight loss with NLRP3 inhibitor NMRA-215.
/ 1679 items
#XY↓
Intellia Pauses Gene Therapy Trials After Patient Develops Severe Liver Injury
Intellia Therapeutics halts MAGNITUDE trials of nex-z gene therapy after patient hospitalization with Grade 4 liver toxicity. Over 650 patients enrolled in ATTR amyloidosis studies.
Guggenheim Bullish on Oruka Therapeutics with $60 Target
Guggenheim starts coverage of Oruka Therapeutics with Buy rating and $60 target, praising its longer-acting antibody drugs for chronic inflammation treatment.
Wells Fargo Upgrades Glaukos: Hidden Growth Driver Spotted
Wells Fargo raises Glaukos price target to $120, citing Epioxa as underappreciated growth catalyst beyond iDose focus. Stock upgrade to Overweight.
Novartis Makes Bold $12 Billion Move with Avidity Biosciences Acquisition in Largest Deal Under CEO Narasimhan
Novartis acquires Avidity Biosciences for $12 billion, gaining access to breakthrough RNA therapeutics for neuromuscular diseases as the Swiss drugmaker prepares for upcoming patent expirations on key drugs.
BofA Boosts Doximity Rating as Drug Ad Strategy Changes
Bank of America raises Doximity to Buy with $82 target as pharma companies redirect ad spending from consumers to doctors amid new FDA regulations.